FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917588909> ?p ?o ?g. }

• W2917588909 endingPage "107547" @default.
• W2917588909 startingPage "107547" @default.
• W2917588909 abstract "The selective α2A adrenoceptor agonist guanfacine reduces hyperactivity and improves cognitive impairment in patients with attention-deficit/hyperactivity disorder (ADHD). The major mechanisms of guanfacine have been considered to involve activation of postsynaptic α2A adrenoceptor in frontal pyramidal neurons. However, the effects of chronic guanfacine administration on catecholaminergic transmissions associated with the orbitofrontal cortex (OFC) remain unclear. To explore the mechanisms of action of guanfacine on catecholaminergic transmission, the effects of its acute local or sub-chronic systemic administration on catecholamine release within pathways from locus coeruleus (LC) to OFC and reticular thalamic nucleus (RTN), from RTN to mediodorsal thalamic nucleus (MDTN), and from MDTN to OFC were determined using multi-probe microdialysis with ultra-high performance liquid chromatography. Acute OFC local administration of guanfacine did not affect catecholamine release in OFC. Acute LC local and sub-chronic systemic administrations of guanfacine reduced norepinephrine release in LC, OFC and RTN, and also reduced GABA release in MDTN, whereas AMPA-induced (perfusion with AMPA into NDTN) releases of l-glutamate, norepinephrine and dopamine in OFC were enhanced by sub-chronic systemic guanfacine administration. This study identified that catecholaminergic transmission is composed of three pathways: direct noradrenergic and co-releasing catecholaminergic LC-OFC pathways and intermediate LC-OFC (LC-RTN-MDTN-OFC) pathway. We demonstrated the dual actions of guanfacine on catecholaminergic transmission: attenuation of direct noradrenergic LC-OFC transmission at the resting stage and enhancement of direct co-releasing catecholaminergic LC-OFC transmission via GABAergic disinhibition in the intermediate LC-OFC pathway. These dual actions of guanfacine probably contribute to clinical actions of guanfacine against ADHD and its comorbid symptoms. This article is part of the Special Issue entitled ‘Current status of the neurobiology of aggression and impulsivity’." @default.
• W2917588909 created "2019-03-02" @default.
• W2917588909 creator A5019801503 @default.
• W2917588909 creator A5038118464 @default.
• W2917588909 creator A5065687996 @default.
• W2917588909 creator A5068078068 @default.
• W2917588909 creator A5083456016 @default.
• W2917588909 creator A5085011782 @default.
• W2917588909 date "2019-09-01" @default.
• W2917588909 modified "2023-09-27" @default.
• W2917588909 title "Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex" @default.
• W2917588909 cites W1493395004 @default.
• W2917588909 cites W1494321187 @default.
• W2917588909 cites W1572280798 @default.
• W2917588909 cites W1612514357 @default.
• W2917588909 cites W1888470382 @default.
• W2917588909 cites W1963507303 @default.
• W2917588909 cites W1969303073 @default.
• W2917588909 cites W1972927648 @default.
• W2917588909 cites W1973664608 @default.
• W2917588909 cites W1973854311 @default.
• W2917588909 cites W1976353043 @default.
• W2917588909 cites W1977587894 @default.
• W2917588909 cites W1985339809 @default.
• W2917588909 cites W1987022586 @default.
• W2917588909 cites W1993201524 @default.
• W2917588909 cites W1995384231 @default.
• W2917588909 cites W2007567296 @default.
• W2917588909 cites W2013070875 @default.
• W2917588909 cites W2014284272 @default.
• W2917588909 cites W2017182954 @default.
• W2917588909 cites W2017847341 @default.
• W2917588909 cites W2036106070 @default.
• W2917588909 cites W2042468643 @default.
• W2917588909 cites W2048207116 @default.
• W2917588909 cites W2064511081 @default.
• W2917588909 cites W2069128820 @default.
• W2917588909 cites W2070709006 @default.
• W2917588909 cites W2070844974 @default.
• W2917588909 cites W2073778004 @default.
• W2917588909 cites W2083977516 @default.
• W2917588909 cites W2087660668 @default.
• W2917588909 cites W2087828327 @default.
• W2917588909 cites W2091152400 @default.
• W2917588909 cites W2092470701 @default.
• W2917588909 cites W2097094466 @default.
• W2917588909 cites W2103982513 @default.
• W2917588909 cites W2109682741 @default.
• W2917588909 cites W2151488696 @default.
• W2917588909 cites W2154917565 @default.
• W2917588909 cites W2163980830 @default.
• W2917588909 cites W2179646396 @default.
• W2917588909 cites W222668809 @default.
• W2917588909 cites W2337823340 @default.
• W2917588909 cites W2338329485 @default.
• W2917588909 cites W2343875542 @default.
• W2917588909 cites W2593068449 @default.
• W2917588909 cites W2599483685 @default.
• W2917588909 cites W2765684626 @default.
• W2917588909 cites W2767055120 @default.
• W2917588909 cites W2767306984 @default.
• W2917588909 cites W2768988444 @default.
• W2917588909 cites W2791419854 @default.
• W2917588909 cites W2792459481 @default.
• W2917588909 cites W2900989290 @default.
• W2917588909 doi "https://doi.org/10.1016/j.neuropharm.2019.02.029" @default.
• W2917588909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30802458" @default.
• W2917588909 hasPublicationYear "2019" @default.
• W2917588909 type Work @default.
• W2917588909 sameAs 2917588909 @default.
• W2917588909 citedByCount "31" @default.
• W2917588909 countsByYear W29175889092019 @default.
• W2917588909 countsByYear W29175889092020 @default.
• W2917588909 countsByYear W29175889092021 @default.
• W2917588909 countsByYear W29175889092022 @default.
• W2917588909 countsByYear W29175889092023 @default.
• W2917588909 crossrefType "journal-article" @default.
• W2917588909 hasAuthorship W2917588909A5019801503 @default.
• W2917588909 hasAuthorship W2917588909A5038118464 @default.
• W2917588909 hasAuthorship W2917588909A5065687996 @default.
• W2917588909 hasAuthorship W2917588909A5068078068 @default.
• W2917588909 hasAuthorship W2917588909A5083456016 @default.
• W2917588909 hasAuthorship W2917588909A5085011782 @default.
• W2917588909 hasConcept C126322002 @default.
• W2917588909 hasConcept C134018914 @default.
• W2917588909 hasConcept C15744967 @default.
• W2917588909 hasConcept C169760540 @default.
• W2917588909 hasConcept C2775894120 @default.
• W2917588909 hasConcept C2776824294 @default.
• W2917588909 hasConcept C2778399450 @default.
• W2917588909 hasConcept C2778514916 @default.
• W2917588909 hasConcept C2780815205 @default.
• W2917588909 hasConcept C513476851 @default.
• W2917588909 hasConcept C71924100 @default.
• W2917588909 hasConceptScore W2917588909C126322002 @default.
• W2917588909 hasConceptScore W2917588909C134018914 @default.
• W2917588909 hasConceptScore W2917588909C15744967 @default.
• W2917588909 hasConceptScore W2917588909C169760540 @default.

• next